Table 2.

Risk of exceeding an age-specific PSA cutpoint, prostate biopsy, and cancer diagnosis by various PSA cutoffs

	Risk of Exceeding Age- specific PSA Cutpoint		Risk of Prostate Biopsy		Risk of Prostate Cancer
Baseline PSA by Quartile	N	HR (95% CI)	N	HR (95% CI)	N	HR (95% CI)
Quartile 1 (<0.5 ng/mL), n =42	0	0	5	(referent)	1	(referent)
Quartile 2 (0.5–0.69 ng/mL), n = 76	3	(referent)	13	1.4 (0.55–4.5)	2	1.03 (0.1–22)
Quartile 3 (0.7–0.99 ng/mL), n = 74	7	2.3 (0.63–10.6)	17	1.9 (0.77–5.9)	3	1.4 (0.2–29)
Quartile 4 (≥1.0 ng/mL), n = 76	21	7.0 (2.4–29.6)	31	3.8 (1.6–11.3)	12	6.3 (1.23–114)
Baseline PSA cutpoint median
PSA <0.7 ng/mL, n = 118	3	(referent)	18	(referent)	3	(referent)
PSA ≥0.7 ng/mL, n = 150	28	7.2* (2.6–30.3)	48	2.2† (1.3–3.9)	15	3.7 (1.2–16.0)
Baseline PSA cutpoint 75th percentile
PSA <1.0 ng/mL, n = 192	10	(referent)	35	(referent)	6	(referent)
PSA ≥1.0 ng/mL, n = 76	21	5.4* (2.6–12.0)	31	2.7† (1.6–4.5)	12	5.3 (2.0–15.1)

CI, confidence intervial; HR, hazard ratio; other abbreviation as in Table 1.

^*Adjusted for age and family history of prostate cancer.

^† Adjusted for age, digital rectal examination, and family history of prostate cancer.